DIABETES IN 2007 What snew
|
|
- Kelley Tucker
- 6 years ago
- Views:
Transcription
1 DIABETES IN 2007 What snew 1 Objectives 1. Review recently published clinical trials in diabetes What does this mean to us? 1. Discuss novel concepts in the treatment of diabetes What should we expect? 2. Introduce future directions in diabetes prevention and management What does the crystal ball hold? 2 1
2 News in 2007 Diabetes in Canada Prevention Treatment Guideline update Novel Concept Future Directions 3 4 2
3 Glycemic Control in Canada One in two type 2 diabetes patients did not reach target A1C ( 7%) Uncontrolled A1C 49% Controlled A1C 51% Harris SB, et al. Diabetes Res Clin Prac 2005;70: Most recent A1C test results (n=2337) 5 Proportion of patients with A1C > 7.0 increases with duration of type 2 diabetes 53% 42% 31% 67% 62% Years T2DM Harris,S et al. CDA 2003; Type 2 Diabetes and Associated Complications in Primary Care in Canada: The Impact of Duration of Disease 6 on Morbid Load. >
4 Glycemic Management: Drug Class Metformin 61% Sulfonylureas net 48% TZDs net 15% Other oral agents net 4% Insulin Lifestyle only 12% 15% Patients currently taking medication (%) Despite suboptimal control, only 12% of patients were receiving insulin Harris SB, et al. Diabetes Res Clin Prac 2005;70: So what does this trial tell us? 1) Current treatment practices are not aggressive enough to manage a substantial proportion of patients. 2) Physicians appear to know the diabetes guidelines, but are not putting them into practice = clinical inertia. 3) They need help with implementing the guidelines, ie, patient/physician-based programs. 8 4
5 We need to provide sufficient support for physicians so that they can offer patients the intensive care that they require. Dr. Stewart Harris, University of Western Ontario. 9 DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication 10 5
6 The DREAM Trial Aims: Design: Sample: Pts: Outcome: Does ramipril 15 mg/d prevent diabetes? Does rosiglitazone 8 mg/d prevent diabetes? 2 X 2 factorial, double-blind RCT Age 30+; IGT (FPG <7 & 2 hr ) &/or IFG (FPG ) 5269 in 191 sites, 21 countries, & F/U 3 yrs Incident DM (confirmed FPG > 7 or 2 hr > 11.1; or MD diagnosis) or death* *because undiagnosed diabetes may be more frequent in those who die 11 than in those who do not Screening & Randomization Screened Excluded: 539 Run-in 5808 Randomized 5269 Excluded: Glucose or Primary Outcome Status in 94% at study end Vital Status in 98% 12 6
7 Summary & Conclusions: Ramipril Modestly improves glycemic status in IFG/IGT A nonsignificant 9% DM reduction Significant 16% increase in regression to normal glucose levels by at least 2 yrs Reduced 2 hr glucose by 0.3 mm by study end Significantly reduces BP in IGT / IFG Small, favourable effect on liver function 13 Summary & Conclusions: Ramipril Meta Analysis showed approximately 14% reduction with ACE inhibitor The DREAM results provide the best estimate of the effect of ACE-Is on diabetes prevention in people with IFG / IGT & no previous CV disease Ramipril cannot currently be recommended for DM prevention However, in people in whom there is an indication for ACE inhibitors (high BP, CHF, vascular disease, high risk DM) the favourable effects on glucose may be of added benefit 14 7
8 Summary & Conclusions: Rosiglitazone A dose of 8 mg/day reduces new DM by > 60% in people with IGT or IFG Promotes regression to normal FPG & 2 hr PG by >70% Effective in all regions of the world Eliminates the gradient of DM risk with increasing weight ~ 3% increase in body weight, but a favourable effect on waist/hip ratio Reduces ALT 15 Summary & Conclusions: Rosiglitazone Modestly lowers systolic BP & diastolic BP Increases the risk of CHF Too few events to draw any conclusions re the effect on other CV events or death For every 1000 people treated with rosiglitazone for ~ 3 years, 144 cases of DM will be prevented with an excess of ~ 4 cases of CHF 16 8
9 Conclusions of the DREAM Trial Rosiglitazone has a substantial benefit on prevention of diabetes & regression to normoglycaemia Ramipril has a modest benefit on regression to normoglycaemia The durability of the glycaemic effect of these drugs was assess in a washout phase. But will this dramatically change how we prevent diabetes??? 17 Intervention studies for diabetes prevention Study Da Qing IGT and Diabetes Study (N = 577) Finnish Diabetes Prevention Study (N = 522) Diabetes Prevention Program Study (N = 3234) TRIPOD (N = 266) STOP-NIDDM (N = 1418) XENDOS (N = 3305) Indian Diabetes Prevention Program (N = 531) Intervention Diet Physical exercise Diet and physical exercise Diet and physical exercise Lifestyle intervention Metformin Troglitazone* Troglitazone* Acarbose Orlistat Lifestyle intervention Metformin Metformin and lifestyle RR (%) * Troglitazone is no longer available Pan XR, et al. Diabetes Care 1997; Tuomilehto J, et al. N Engl J Med 2001; Knowler WC, et al. N Engl J Med , 2004; Buchanan TA, et al. Diabetes 2002;51: ; Ramachandran A. 4th World Congress on Prevention of Diabetes and its Complications, Chennai Feb 2005; Chiasson JL, et al. Lancet 2002; Torgerson JS, et al. Diabetes Care
10 A Diabetes Outcomes Progression Trial An international, long-term, double-masked, randomised clinical trial to evaluate whether the thiazolidinedione rosiglitazone provides more durable and safe glycaemic control than the biguanide metformin or the sulphonylurea glyburide (glibenclamide) ADOPT Timeline START: 28 February 10 April: 1st patient randomised June: Recruitment completed 27 February: All baseline data in house FINISH: 13 June 20 10
11 Run-In 4 weeks ADOPT Design Treatment Period 4 to 6 years Rosiglitazone (N =1456) Diet/exercise reinforcement Metformin (N = 1454) Glyburide (N = 1441) Clinic visits every 2 months for 1 yr, then every 3 months Randomisation Study end 21 Primary Outcome: Monotherapy Failure FPG >10 mmol/l OR.Administrative withdrawal Secondary Outcomes Confirmed FPG >7.8 mmol/l Remaining on monotherapy with HbA1c <7% Longitudinal collection of glycaemic measures, anthropometrics, insulin sensitivity and beta-cell function 22 11
12 Cumulative Incidence of Monotherapy Failure (FPG >10 mmol/l) Rosiglitazone vs Metformin 32% risk reduction, P<0.001 Rosiglitazone vs Glyburide 63% risk reduction, P<0.001 Glyburide Percent Metformin Rosiglitazone Patients at Risk Rosiglitazone Metformin Glyburide Time (years) Cumulative Incidence of FPG >7.8 mmol/l Among Patients with Baseline FPG 7.8 mol/l Rosiglitazone vs Metformin 36% risk reduction, P=0.002 Rosiglitazone vs Glyburide 62% risk reduction, P<0.001 Glyburide Percent Metformin Rosiglitazone Patients at Risk Rosiglitazone Metformin Glyburide Time (years)
13 HbA1c Over Time Rosiglitazone vs Metformin 0.13 ( 0.22 to 0.05), P=0.002 Rosiglitazone vs Glyburide 0.42 ( 0.50 to 0.33), P<0.001 Glyburide Metformin % 7.0 Rosiglitazone Time (years) 25 Durability of Glycaemic Control: Time to Mean HbA 1c >7% Glyburide 33 Metformin 45 Rosiglitazone Months 26 13
14 Adverse Events Rosiglitazone was associated with weight gain and oedema, and in women, fractures Metformin was associated with adverse gastrointestinal events Glyburide was associated with hypoglycaemia and weight gain Rosiglitazone and metformin had a similar risk of cardiovascular events. Glyburide had a lower risk of cardiovascular events than rosiglitazone 27 Limitation The proportion of patients who withdrew from the study was high Rosiglitazone 37% Metformin 38% Glyburide 44% But The characteristics of patients who withdrew were similar among groups Sensitivity analyses showed that withdrawals did not appear to bias efficacy results 28 14
15 Clinical Implications The progressive hyperglycaemia of type 2 diabetes can be slowed Rosiglitazone was most effective, probably due to its positive effects on both insulin sensitivity and beta-cell function Use of rosiglitazone early in the course of the disease is preferable to the use of glyburide Use of rosiglitazone as initial monotherapy in type 2 diabetes requires a full appreciation of its efficacy, adverse event profile and cost 29 DYSLIPIDEMIA GUIDELINES 2006 Achieving an LDL-C of <=2.0 mmol/l is the primary goal of therapy. Once the LDL-C goal has been attained, consideration to achieving the secondary target of an TC/HDL-C ratio of <4.0. The vast majority of patients with be able to attain the LDL-C goal on statin therapy. Although not formal goals of therapy, optimal TG is <1.5 mmol/l and apo B is 0.9 g/l Lifestyle modification should be seen as an important adjunct to, not substitution for, pharmacologic therapy. CDA CPG Expert Committee. Can J Diabetes. 2006;30:
16 DYSLIPIDEMIA Effective risk reduction requires a multifaceted approach targeting all risk factors: -Obesity - Hypertension - Hyperglycemia - Dsylipidemia - Microalbuminuria -Smoking - Sedentary lifestyle -Diet CDA CPG Expert Committee. Can J Diabetes. 2006;30: Action to Control the Cardiovascular Risk Of Diabetes-ACCORD TRIAL Designed to test the effects on major CVD events of: intensive glycemia control treatment to increase HDLcholesterol and lower triglycerides (in the context of good LDL-C and glycemia control) of intensive blood pressure control (in the context of good glycemia control)
17 ACCORD Treatment goals: Glycemia intensive HbA1c <6%; - conventional target 7.5% Blood pressure intensive systolic < conventional systolic < 140 Lipids LDL C blinded but < 3.10 On either Zocor and Fibrate/Placebo in a double blind fashion Substudies MIND EYE GENETICS BONE 33 EDIC EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS Long term follow-up of DCCT 10 years and going A1C similar in both groups Microvascular disease still decreased in intensive group Cardiovascular disease 37% reduction in intensive versus conventional Glucose markers and mechanism more to come 34 17
18 DYSLIPIDEMIA RECOMMENDATIONS Most adults with type 1 or type 2 diabetes should be considered at high risk for vascular disease [Grade A, Level 1, Level 2]. The exceptions are younger adults with shorter duration of disease and without complications of diabetes (including established CVD) and without other CVD risk factors [Grade A, Level 1]. A computerized risk engine (e.g. UKPDS risk engine, Cardiovascular Life Expectancy Model) can be used to estimate vascular risk [Grade D, Consensus]. CDA CPG Expert Committee. Can J Diabetes. 2006;30: DYSLIPIDEMIA RECOMMENDATIONS In adults with serum TG >10.0 mmol/l despite best efforts at optimal glycemic control and other lifestyle interventions (e.g. weight loss, restriction of refined carbohydrates and alcohol), a fibrate should be prescribed to reduce the risk of pancreatitis [Grade D, Consensus]. For those with moderate hyper-tg (4.5 to 10.0 mmol/l), either a statin or fibrate can be attempted as first-line therapy, with the addition of a second lipid-lowering agent of a different class if target lipid levels are not achieved after 4 to 6 months on monotherapy [Grade D, Consensus]. CDA CPG Expert Committee. Can J Diabetes. 2006;30:
19 New Guidelines: March WHAT SHOULD WE EXPECT IN 2007? 38 19
20 INCRETINS Gut peptides GLP-1(glucagon-like peptide-1) GIP (glucose dependent insulinotropic peptide or gastric inhibitory polypeptide) Incretins secreted from the gut during CHO absorption and increase insulin secretion Both are rapidly inactivated in the circulation by DPPIV (dipeptidyl peptidase IV) Incretin stimulation is thought to account for 30-60% of post prandial insulin release Insulintropic effects of both are dependent on blood glucose level being elevated above basal level So working on GLP1 and DPPIV 39 Synthesis and Secretion of GLP-1 and GIP L-Cell (ileum+ colon) Proglucagon K-Cell (jejunum) ProGIP GLP-1 [7-37] GIP [1-42] GLP-1 [7-36NH 2 ] 40 20
21 Overlapping and Contrasting Actions of GLP-1 and GIP GLP-1 Released from L cells in ileum and colon Stimulates insulin release from β-cell Potent inhibition of gastric emptying Potent inhibition of glucagon secretion Reduction of food intake and body weight Significant effects on β-cell growth and survival Insulinotropic actions preserved in type 2 diabetes Drucker DJ. Diabetes Care. 2003;26: GIP Released from K cells in duodenum Stimulates insulin release from β-cell Modest effects on gastric emptying No significant inhibition of glucagon secretion No significant effects on satiety or body weight Potential effects on β-cell growth and survival Defective insulinotropic action in type 2 diabetes 41 Summary of Incretin Actions on Different Target Tissues Brain Neuroprotection Appetite Stomach Heart Gastric emptying Liver Cardioprotection Cardiac output Glucose production Drucker D. J. Cell Metabolism 2006 Insulin sensitivity Muscle GLP-1 GI tract Insulin secretion Glucagon secretion Insulin biosynthesis β cell proliferation β cell apoptosis 42 21
22 Incretin Secretion and DPP-4 Mediated Inactivation Mixed Meal Intestinal GIP Release Intestinal GLP-1 Release GIP (1-42) Active Decreased gastric emptying, food intake and glucagon secretion GLP-1 (7-36) Active DPP-4 t 1/2 = 1 to 2 min Increased insulin secretion Enhanced β-cell proliferation Reduced β-cell apoptosis Reduced glucagon secretion (GLP-1) Drucker DJ. Diabetes Care 2003;26: DPP-4i GLP-1 (9-36) Inactive (> 80% of pool) 43 Differentiation vs. other therapies Inhibition of DPP-IV: different to: Novel mode of action (Combined Insulin Secretion and Sensitization) Effects on GLP-1 and GIP GLP-1 analogues Potential for Beta Cell Protection Very low risk of hypoglycemia SU, insulin 2 safeguards:- meal dependant insulin secretion -plasma glucose dependent insulin secretion No safety restrictions (contraindications e.g. renal, CHF) BW: at least no BW gain PPAR, metformin PPAR, insulin, SU 44 22
23 Non-Insulin Injectables What is up with that. 45 GLP-1 Exenatide (Byetta) approved in the US SC injection once daily Others in development NN and sa Naturally occuring GLP-1 feeds back from gut to pancreas to increase insulin production in response to food Nausea weight loss decreased GI motility decreased glucose excursions Type 2 diabetes 46 23
24 AMYLIN Amylin is a hormone?? secreted by the pancreas Secreted with insulin and glucagon Deficient in diabetes (likely both) Reduces gastric motility and thereby reducing glucose excursion Available in US as Symlin NAUSEA +++ Weight loss Can mix with insulin Dose with each meal Place in the tool box yet to be determined 47 Alternative Delivery Inhaled insulin Pfizer FDA Approved Being worked on by Eli Lilly Novo Nordisk MANKIND 48 24
25 Glucose Infusion Rate (mg/kg/min) Time-Action Profile Glucose Infusion Rate Inhaled Insulin* Insulin Lispro Regular Insulin Time (min) Heise T. et al. Diabetes 2000;49(Suppl 1):A10 49 Inhaled Insulin What do we tell our patients? replaces short-acting insulin injections at meals in Type I diabetes: still requires longer-acting insulin injections by needle to supply basal insulin needs at present has been approved and marketed in US Canadian approval pending early results indicate similar sugar control to conventional short-acting insulin by injection Studies comparing to Rapid insulin ongoing cannot be used by smokers Will required frequent PFT testing 50 25
26 ORAL AGENTS What s coming?? DPPIV Sitagliptin Merck - JANUVIA Vildagliptin Novartis - GALVUS Saxagliptin BMS Many others in development Working On Designer sensitizers Renal glucose absorption inhibitors 51 Dec, 2003 issue 52 26
27 The Population is Getting Heavier 53 WEIGHT LOSS AGENTS Endocannaboid system novel target Blockade of cannabinoid CB 1 receptor Stimulation of these receptors results in lipogenesis and decreased adiponectin Activation of the endocannabiniod system through CB 1 plays an important role in both the central and peripheral regulation of energy, balance, body weight and food intake. Rimonabant (Acomplia) is a selective CB 1 receptor blocker clinical trials decreased food intake, weight, waist (visceral obesity), lipids, glucose and A1c improve insulin sensitivity and adiponectin -??independent of weight loss Many other similar compounds in development 54 27
28 Islet Cell Transplants No real new updates Disappointing news at best Wait for the official word 55 COMPLICATIONS NOT MUCH IS NEW Protein Kinase C Microvascular disease Retinopathy Nephropathy Obesity - New agents Neuropathy Pregabalin/and more Many outcome trials are ongoing AND WHAT EVER ELSE 56 28
29 Diabetes In Summary What do newly published clinical trial mean to us? What novel concept should we expect? What does the crystal ball hold? 57 We are trying but Author unknown HOLD ON TO YOUR HATS _ THE BEST IS YET TO COME 58 29
Type 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationPractical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua
Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationOptimal glucose control. DM Treatment. Glucose Control one out of many. Many guidelines: Confusing. Theorectically easy
DM Treatment How to Achieve Optimal Glycaemic Control The Tung Wah Eastern Hospital Experience of DM Share Care Experience Optimal glucose control Theorectically easy More challenging in the real world
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationCopyright 2017 by Sea Courses Inc.
Pre-Diabetes: Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical,
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationDiscussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting
Session #5 Cardiometabolic Risk Management in the Primary Care Setting Sonja Reichert, MD MSc FCFP FACPM Betty Harvey, RNEC BScN MScN Amanda Mikalachki, RN BScN CDE S Discussion points Whom should we be
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationPre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes
Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including
More informationScope. History. History. Incretins. Incretin-based Therapy and DPP-4 Inhibitors
Plasma Glucose (mg/dl) Plasma Insulin (pmol/l) Incretin-based Therapy and Inhibitors Scope Mechanism of action ผศ.ดร.นพ.ว ระเดช พ ศประเสร ฐ สาขาว ชาโภชนว ทยาคล น ก ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationA New Therapeutic Strategey for Type II Diabetes: Update 2008
Live, One Hour Webinar A New Therapeutic Strategey for Type II Diabetes: Update 2008 Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy in Grundy, Virginia.
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationTreating Type 2 Diabetes with Bariatric Surgery. Goal of Treating T2DM. Remission of T2DM with Bariatric
Treating Type 2 Diabetes with Bariatric Surgery Number (in Millions) of Persons with Diagnosed Diabetes, United States, 198 25 The number of Americans with diabetes increased from 5.6 to 15.8 million Guilherme
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationManagement of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationDiabetes in the UK: Update on Diabetes Treatment and Care. Why is diabetes increasing? Obesity Increased waist circumference.
Update on Diabetes Treatment and Care Tahseen A Chowdhury Consultant Diabetologist Royal London and Mile End Hospitals Diabetes prevalence (thousands) Diabetes in the UK: 1995-21 3 25 2 15 1 5 Type 1 Type
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationCURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2013 BMI
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationManagement of Diabetes Mellitus: A Primary Care Perspective
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationPancreatic b-cell Dysfunction in Type 2 Diabetes ZIAD KAHWASH, M.D. Insulin resistance: Defects in Insulin Signaling
Plasma insulin (mu/ml) ZIAD KAHWASH, M.D. resistance: Defects in Signaling Increased glucose production Glucose Insufficient glucose disposal X Liver glucagon insulin Pancreas Peripheral tissues (skeletal
More informationDPP-4 inhibitor. The new class drug for Diabetes
DPP-4 inhibitor The new class drug for Diabetes 1 Cause of Death in Korea 1 st ; Neoplasm 2 nd ; Cardiovascular Disease 3 rd ; Cerebrovascular Disease Diabetes 2 Incidence of Fatal or Nonfatal MI During
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationGlycemic control what can be achieved with life-style and when and how to use pharmacological agents?
Glycemic control what can be achieved with life-style and when and how to use pharmacological agents? Eberhard Standl Munich Diabetes Research Institute At the Munich Helmholtz Center Pathogenetic key
More informationVipul Lakhani, MD Oregon Medical Group Endocrinology
Vipul Lakhani, MD Oregon Medical Group Endocrinology Disclosures None Objectives Be able to diagnose diabetes and assess control Be able to identify appropriate classes of medications for diabetes treatment
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationMr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)
Dr David Kim Endocrinologist and General Physician Waitemata DHB and Apollo Specialist Clinic Albany Auckland Mr Rab Burtun Diabetes Nurse Specialist Waitemata DHB Waitakere Hospital Auckland 8:30-10:30
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationNovel anti-diabetic therapies
Prof. Manfredi Rizzo, MD, PhD ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of Palermo, Italy & ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of South
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationCURRENT STATEGIES IN DIABETES MELLITUS DIABETES. Recommendations for Adults CURRENT STRATEGIES IN DIABETES MELLITUS. Diabetes Mellitus: U.S.
CURRENT STATEGIES IN DIABETES MELLITUS Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Diabetes Mellitus: U.S. Impact ~1 Million Type 1 DIABETES 16.7 Million IFG (8.3%) 12.3
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationDr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?
Dr Tahseen A. Chowdhury Royal London Hospital New Guidelines in Diabetes: NICE or Nasty? I have no conflicts of interest I do not undertake talks / advisory bodies / research for any pharma company Consultant
More informationEffect of macronutrients and mixed meals on incretin hormone secretion and islet cell function
Effect of macronutrients and mixed meals on incretin hormone secretion and islet cell function Background. Following meal ingestion, several hormones are released from the gastrointestinal tract. Some
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationGLP-1-based therapies in the management of type 2 diabetes
GLP-1-based therapies in the management of type 2 diabetes Makbul Aman Mansyur Division Endocrine & Metabolism Department of Internal Medicine Faculty of Medicine Hasanuddin University/ RSUP Dr. Wahidin
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationCURRENT ISSUES IN DIABETES MANAGEMENT
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact DIABETES
More informationDiabetic Management of the Cardiac Patient
Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:
More informationT2DM is a global epidemic with
: a new option for the management of type 2 diabetes Marc Evans MRCP, MD, Consultant Diabetologist, Llandough Hospital, Cardiff Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present
More informationPrediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes!
Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Jaini Patel, PharmD, BCACP Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Kathleen
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More information22 Emerging Therapies for
22 Emerging Therapies for Treatment of Type 2 Diabetes Siddharth N Shah Abstract: The prevalence of Diabetes is progressively increasing world-wide and the growth of the disease in our country is phenomenal.
More informationComparative Effectiveness and Safety of Diabetes Medications for Adults with Type 2 Diabetes
Draft Comparative Effectiveness Review Comparative Effectiveness and Safety of Diabetes Medications for Adults with Type Diabetes Prepared for: Agency for Healthcare Research and Quality U.S. Department
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationType 2 Diabetes. Treat to: limit complications maintain quality of life Improve survival
Type 2 Diabetes Treat to: limit complications maintain quality of life Improve survival 1 Criteria for the diagnosis of diabetes 1. HbA1C 6.5% (rounded to 50mmol/mol). 2. FPG 7.0 mmol/l. 3. 2-h plasma
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationProfessional s Guide to Treatment
TYpe2diabetes A Healthcare Professional s Guide to Treatment BY RObin J. COnway, MD www.diabetesclinic.ca - transform your experience through learning - CONTENTS Diabetes basics 3 Diabetes in Canada 5
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More information